Furthermore, Knapper et al. also proved that lestaurtinib and chemotherapy as first-line therapy did not prolong 5-year overall or relapse-free survival of younger patients with untreated FLT3-mutated AML from the UK AML15 and AML17 trials (Table 3) [41]. Here, FLT3 is linked to acute myeloid leukemia.